4//SEC Filing
Bozigian Haig P. 4
Accession 0001209191-21-009130
CIK 0000914475other
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 9:27 PM ET
Size
18.3 KB
Accession
0001209191-21-009130
Insider Transaction Report
Form 4
Bozigian Haig P.
Sr Vice President, Development
Transactions
- Sale
Common Stock
2021-02-08$116.85/sh−824$96,286→ 154,934 total - Award
Stock Option
2021-02-08+3,188→ 3,188 totalExercise: $117.63Exp: 2031-02-08→ Common Stock (3,188 underlying) - Award
Restricted Stock Unit
2021-02-08+532→ 532 total→ Common Stock (532 underlying) - Sale
Common Stock
2021-02-05$113.79/sh−704$80,109→ 153,328 total - Sale
Common Stock
2021-02-08$116.78/sh−1,395$162,912→ 156,189 total - Sale
Common Stock
2021-02-08$116.79/sh−1,623$189,550→ 157,651 total
Footnotes (11)
- [F1]Sale of 704 shares of common stock issued upon vesting of 1,338 restricted stock units on February 5, 2021 to cover payroll and withholding taxes, with the balance of the shares (634) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F10]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
- [F11]The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.66 to $116.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Sale of 824 shares of common stock issued upon vesting of 2,430 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,606) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above.
- [F4]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.97 to $117.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F5]Sale of 1,395 shares of common stock issued upon vesting of 2,650 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,255) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F6]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.90 to $117.84. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F7]Sale of 1,623 shares of common stock issued upon vesting of 3,085 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,462) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F8]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.99 to $117.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F9]Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
Documents
Issuer
NEUROCRINE BIOSCIENCES INC
CIK 0000914475
Entity typeother
Related Parties
1- filerCIK 0001423837
Filing Metadata
- Form type
- 4
- Filed
- Feb 8, 7:00 PM ET
- Accepted
- Feb 9, 9:27 PM ET
- Size
- 18.3 KB